Longevity Health Holdings, Inc. · OTC:XAGE
Longevity Health — Carmell — Merger or Acquisition (August 2023)
5 slides from Longevity Health's merger presentation, Aug 1, 2023
Slide 1: Background/Timeline
BACKGROUND/TIMELINE 1. Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) announced execution of definitive Merger Agreement with Carmell Therapeutics on Jan 4, 2023 2. Began due diligence and negotiations for potential bolt-on acquisition of Axolotl Biologix on March 20, 2023 3. Announced non-bi
Slide 2: Creating Shareholder Value: Acquisitions & Deal Making
CREATING SHAREHOLDER VALUE: ACQUISITIONS & DEAL MAKING ALPA ALPA New Ticker: CTCX CTCX Nasdaq listed 100% 100% 100% Candy Merger Sub Carmell Therapeutics Carmell Therapeutics Carmell Therapeutics Axolotl 1 Biologix TargetCo 3 Target Evaluation Merger Announced in Jan 2023 Merger Closed in July 2023
Slide 3: Business Overview
BUSINESS OVERVIEW Carmell Axolotl Biologix Facilities Pittsburgh, PA Flagstaff, AZ Employees 25 15 (full-time + part-time) Technology Allogeneic Platelet Rich Plasma Human amnion allografts • R&D programs in skin and • Commercial products aimed at bone healing skin healing (diabetic foot ulcers, • P
Slide 4: Peer Valuation
PEER VALUATION Enterprise Value, R&D expense/ Est FY23 Revenue Source: CapitalIQ Debt/Equity EV/TTM Revenue EV/TTM EBITDA $M Revenue Growth Profitable companies Artivion 968 45% 11% 7.0% 3.0x 25.1 NuVasive 2,936 40% 8% 7.0% 2.4x 13.9 Integra LifeSciences 4,861 39% 11% 1.3% 3.1x 12.5 Globus Medical 5
Slide 5: Disclaimer
DISCLAIMER This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation of Carmell Therapeutics (the “Company”). The information contained herein does not purport to be all-inclusive and of the Company nor any of their respective a